Pharmaceutical packaging

Pharma is in scope. The derogations are narrower than most teams assume.

PPWR kept pharmaceutical and medical device packaging deliberately in scope, with limited health-and-safety-based derogations rather than blanket relief. Knowing which parts of your portfolio those derogations actually cover, and evidencing it, is the work.

Book a 30-minute call Take the readiness check

What tends to get missed

Most pharmaceutical packaging teams know an exemption exists. Fewer have established where it stops, and that boundary is where the exposure sits.

The derogations attach to immediate packaging, not the whole pack. Relief from certain recyclability and recycled-content requirements is directed at packaging in direct contact with the medicinal product. Secondary cartons, outer packaging and transport packaging generally remain subject to the wider requirements unless a specific derogation applies to them.
An exemption has to be documented, not assumed. The position is product-specific and needs evidence behind it. A portfolio-wide assumption that pharma is exempt is not a defensible compliance position.
Redesign lead times are unlike any other sector. Changing a primary packaging material can trigger a regulatory variation and real-time stability testing running to years. Where a format does need to change, the runway is measured against that timeline, not against the regulatory deadline.
EPR is unaffected by any of it. National registration and reporting obligations run independently of PPWR conformity, market by market, whatever derogations apply to the packaging itself.
Labelling obligations sit alongside existing pharmaceutical requirements. They do not replace them, and the artwork implications need planning against cycles that are already tightly controlled.

These are structural features of the regulation rather than settled detail. Requirements continue to be developed through delegated and implementing acts, and the position for any given pack depends on its specific function and market. Verify against Regulation (EU) 2025/40 and the Commission's PPWR FAQ. Nothing here is legal advice.

The work

Where I come in

The question is rarely whether PPWR applies. It is which parts of a portfolio are genuinely covered by a derogation, which are not, and what evidence stands behind each call.

That means going pack by pack rather than accepting a sector-level assumption, and building a position that holds when a customer, regulator or auditor asks how it was reached.

Portfolio classification. Which packs, and which components within them, fall inside a derogation and which carry the full obligations.
Evidence and documentation. The reasoning behind each classification, recorded so it can be defended rather than reconstructed later.
EPR across markets. Obligation mapping, registration position and reporting method, market by market.
Prioritisation. Where redesign is unavoidable, sequencing it against variation and stability timelines rather than regulatory dates alone.
Supplier alignment. What to ask suppliers for, and what constitutes adequate evidence when it comes back.

Relevant experience

Multi-market packaging compliance programme, pharmaceutical sector

Advisory lead on a packaging PPWR and EPR compliance programme for a pharmaceutical client across European markets. Set the country-by-country obligation strategy, prioritised markets by regulatory risk, steered authorised representative and PRO appointments, and built the registration and reporting methodology the client team now runs independently.

How engagements are scoped

Three fixed-scope routes, depending on where you are. Each is agreed upfront, with no open-ended billing.

Packaging Exposure & Readiness Audit

Establishes where the portfolio stands: which packs are covered by a derogation, which are not, where documentation is missing, and what needs attention first.

Packaging Strategy & Transition Roadmap

For formats that need to change. Sequences the work against variation and stability timelines, with supplier alignment and an implementation plan your teams can run.

Fractional Packaging & Circularity Advisor

Ongoing access for new pack sign-offs, supplier claim verification and keeping pace as delegated acts land and the position shifts.

See full scope and how each is agreed →